Free Newsletter
MediGene, Johns Hopkins join on HPV vax research
MediGene, a Martinsried/Munich-based biotech, and The Johns Hopkins University will work together to create HPV vaccine candidates using the German firm's AAVLP platform. The preclinical program uses adeno-associated viruses as the basis for the vaccine and antigenic peptides to induce specific antibody reactions. MediGene hopes the platform can be used for viral infection and cancer vaccines as well. Release
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
More Research Reports >>
SHARE
WITH: